Skip to main content Skip to navigation
Menu
800-789-7366

Trinity J. Bivalacqua, MD, PhD

Urology
headshot of Trinity J. Bivalacqua, MD, PhD
4.8 with 304 ratings

Sees patients age 18 and up

Trinity J. Bivalacqua, MD, PhD

Urology
4.8 with 304 ratings

Sees patients age 18 and up

  • Director, Urologic Oncology
  • Co-Director, Genitourinary Cancer Service Line, Abramson Cancer Center
  • Professor of Surgery at the Hospital of the University of Pennsylvania
  • Dr. Bivalacqua is a Penn Medicine physician. In New Jersey, providers are affiliated with Penn Medicine through Clinical Health Care Associates of New Jersey or Princeton Healthcare Affiliated Physicians, PC.
Call 800-789-7366 Request Appointment

Meet Dr. Bivalacqua

I am a board-certified urologist with training and expertise in urologic cancers and sexual dysfunction. I am the Director of Urologic Oncology and Co-Director of the Genitourinary Cancer Service Line in the Abramson Cancer Center at Penn. My areas of expertise include the surgical management of prostate, bladder, penile, and upper tract urothelial cancers. I have expertise in open, endoscopic, laparoscopic and robotic surgery and am equipped to individualize treatment options for patients with a wide range of genitourinary malignancies. My other areas of focus include surgical management of erectile dysfunction (inflatable penile prosthesis) and continent urinary diversion (orthotopic neobladder). I strive to offer all my patients organ sparing approaches to treatment of their urologic cancers and my goal is to provide them with the best quality of life following complex cancer and reconstructive surgeries for advanced pelvic malignancies.

There are numerous reasons why patients come to Penn for the best cancer care. Our multidisciplinary urologic cancer team consists of a team of oncologists and surgeons who invest in all aspects of a patient's medical care including tumor sequencing, enrollment in clinical trials, performing world class cancer surgeries, and administering treatments from standard chemotherapy to targeted immunotherapies. The collaborative spirit at Penn is truly outstanding! My goal is to provide patients with a personalized approach to their urologic cancer treatment which is informed by tumor biology and patient preference.

My research program includes a basic translational research lab focusing on cancer immunology of urothelial cancer and tissue engineering approaches to regenerate the lower urinary tract. Our goal is to make discoveries in the research laboratory that can be translated into human clinical trials for management of bladder cancer and erectile dysfunction. I am also involved in surgical education and outcomes research as well as national guidelines panels. I have received multiple awards and recognition for my leadership in urologic oncology, sexual dysfunction and translational research including the American Urological Association (AUA) Rising Star Award and the AUA Gold Cystoscopy Award which is given to the individual who has contributed the most to the field of Urology within the first ten years of practice.

I may be known in the medical community for performing complex surgeries and cutting edge translational research but it's the intense satisfaction I get from helping both men and women with urologic cancers that excites me the most! For this reason, I work with a number of national society boards and advocacy groups including the AUA, the Sexual Medicine Society of North America, the Society of Urologic Oncology and the Bladder Cancer Advocacy Network, to help give back to patients who will benefit from standardization of treatment for urologic cancers and sexual dysfunction.

Back To Top